Drug intelligence / Profile preview

AT1391

Development stage: Preclinical
Modality: Small Molecules
Administration: Transdermal

Overview

AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes. The patch aims to deliver insulin transdermally, offering an alternative to traditional subcutaneous injections for basal insulin therapy. This approach may improve patient compliance and comfort by providing a non-invasive, steady release of insulin throughout the day[1].

Targets

INSR (Insulin receptor)

Beyond the preview

Go deeper on AT1391.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AT1391.

Explore the full profile